Sweetgoals for Type 1 Diabetes
Thinking Outside the Clinic: A Digital Health Approach for Young Adults With Type 1 Diabetes
2 other identifiers
interventional
300
1 country
1
Brief Summary
The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes. All participants will receive the "core" digital intervention, the SweetGoals app, focused on self-monitoring and goal setting. Efficacy of two independent intervention components (incentives for adherence and web health coaching) will be tested
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 16, 2020
CompletedFirst Posted
Study publicly available on registry
November 30, 2020
CompletedStudy Start
First participant enrolled
July 25, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2025
CompletedResults Posted
Study results publicly available
August 13, 2026
CompletedAugust 13, 2026
July 1, 2026
3.8 years
November 16, 2020
April 1, 2026
July 21, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Percent Glycated Hemoglobin/6 Months
Estimated mean change (slope) in percent glycated hemoglobin per each 6 month interval from Baseline to Month 12 were obtained from a growth curve analysis using maximum likelihood estimation to account for missing data. All randomized participants were utilized in the model (ITT analysis).
From Baseline to Month 12
Change in Hba1c at 12 Months, Main Effects of Each Intervention Component
Estimated mean change from Baseline to Month 12 were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months vs. baseline associated with the On level of the intervention condition relative to the Off level of the intervention condition.
12 months, controlling for baseline
Secondary Outcomes (6)
Change in Percent Glycated Hemoglobin Per Day of Glucose Checking Goal Achievement
At 12 months, controlling for baseline
Change in Percent Glycated Hemoglobin Per Day of Mealtime Goal Achievement
At 12 months, controlling for baseline
Days Per Week Meeting Glucose Checking Goal During Intervention Period, Main Effects of Each Intervention Component
Baseline to 6 months
Days Per Week Meeting Mealtime Goal During Intervention Period, Main Effects of Each Intervention Component
Baseline to 6 months
Change in Percent Glycated Hemoglobin Due to Each Intervention Mediated by Days Met Glucose Checking Goal
Baseline to 12 months
- +1 more secondary outcomes
Study Arms (4)
Sweetgoals app
EXPERIMENTALSweetgoals app, incentives
EXPERIMENTALSweetgoals app, coaching
EXPERIMENTALSweetgoals app, incentives, coaching
EXPERIMENTALInterventions
App provides weekly feedback about behavioral goals
Financial incentives for meeting goals
Eligibility Criteria
You may qualify if:
- Have a diagnosis of T1D for \>18 months
- Have A1c ≥7.5%
- Report a visit with physician managing type 1 diabetes (T1D) within the previous 6 months
- Participants must use a glucometer or continuous glucose monitor compatible with Glooko.
You may not qualify if:
- Pregnancy or breast feeding
- Severe medical illness that would preclude participation (e.g., cystic fibrosis, developmental disability, severe cognitive impairment)
- Psychiatric illness that would preclude participation
- Diabetes diagnoses other than T1D (Type 2 Diabetes, Maturity Onset Diabetes of the Young/MODY)
- Use of any medications known to impact glycemic control (oral or injectable corticosteroids, beta-blockers, antipsychotic medications such as risperidone).
- A history of known hemoglobinopathy, anemia, or transfusion (which could alter the validity of HbA1c measurement)
- Already being engaged in a psychological intervention targeting diabetes adherence.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dartmouth College
Hanover, New Hampshire, 03755, United States
Related Publications (3)
Yallampalli H, Plaitano EG, Stanger C. Technology readiness associated with insulin pump and automated insulin delivery system use in young adults with type 1 diabetes. J Health Psychol. 2026 Mar 29:13591053261433230. doi: 10.1177/13591053261433230. Online ahead of print.
PMID: 41906546DERIVEDPlaitano EG, Stanger C. Joint effect of nicotine use and diabetes distress on glycemic control in young adults with type 1 diabetes. J Diabetes Complications. 2025 Aug;39(8):109083. doi: 10.1016/j.jdiacomp.2025.109083. Epub 2025 May 17.
PMID: 40398346DERIVEDStanger C, Kowatsch T, Xie H, Nahum-Shani I, Lim-Liberty F, Anderson M, Santhanam P, Kaden S, Rosenberg B. A Digital Health Intervention (SweetGoals) for Young Adults With Type 1 Diabetes: Protocol for a Factorial Randomized Trial. JMIR Res Protoc. 2021 Feb 23;10(2):e27109. doi: 10.2196/27109.
PMID: 33620330DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Catherine Stanger
- Organization
- Dartmouth College
Study Officials
- PRINCIPAL INVESTIGATOR
Catherine Stanger, Ph.D.
Trustees of Dartmouth College
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
November 16, 2020
First Posted
November 30, 2020
Study Start
July 25, 2021
Primary Completion
April 30, 2025
Study Completion
April 30, 2025
Last Updated
August 13, 2026
Results First Posted
August 13, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- If the study ends and data are no longer being obtained directly from study participants by study investigators, all study data will be provided to the Repository by the end of the funding period (which may include no-cost extensions). The period of exclusive use of the entire dataset from the study will be for three years after the last study contact for collection of intervention outcomes.
- Access Criteria
- Data requests made directly to the Principal Investigator or through the NIDDK Data Repository
Data will be made available to other researchers and practitioners, while safeguarding the privacy of participants and protecting confidential and proprietary data and third-party intellectual property. Findings will be published as soon as they are available in relevant peer-reviewed journals that are available online, and share as requested directly to the author(s). Data requests can be made directly to the Principal Investigator with information for accessing the data on the NIDDK Data Repository.